Protagonist Therapeutics, Inc. (PTGX) Presents At Citi's Biopharma Back To School Conference Transcript

Protagonist Therapeutics detailed its strategy for developing differentiated oral peptide therapeutics, emphasizing its versatile platform and strategic partnerships. The company highlighted outstanding Phase III data and Breakthrough Designation for its lead asset, rusfertide for polycythemia vera, noting a pending NDA filing and a partnership with Takeda that includes a significant $400M opt-out fee or rich royalties. Furthermore, the J&J-partnered oral IL-23 blocker, icotrokinra, has an NDA filed for psoriasis and strong IBD data, positioning it to capture a substantial market due to its oral convenience. Protagonist is also advancing promising early-stage oral programs in obesity (PN-477) and inflammation (PN-881) into Phase I, underscoring its pipeline expansion and focus on high-potential oral therapies.

Analysis

Protagonist Therapeutics is executing a focused strategy on developing differentiated oral peptide therapeutics for validated biological pathways, significantly de-risking its pipeline. The company's lead asset, rusfertide for polycythemia vera, has demonstrated "outstandingly positive" Phase III data and secured a Breakthrough Therapy Designation, with an NDA filing projected by year-end. A critical near-term catalyst is the partnership decision with Takeda, which presents a choice between a 50/50 profit share or a significant ~$425 million opt-out payment coupled with a rich royalty stream of 14-29%. The second major value driver, the J&J-partnered oral IL-23 blocker icotrokinra, has an NDA filed for psoriasis and has shown "stellar" Phase II results in ulcerative colitis, including 30% clinical remission. J&J's bullish guidance of $1.4 billion in 2027 sales—double the previous consensus—and aggressive development across four major indications underscore the significant royalty potential for Protagonist. Beyond these late-stage assets, the company is advancing a high-potential early-stage pipeline, notably entering the competitive obesity market with PN-477, a "triple-G" agonist with promising preclinical data, and advancing its oral IL-17 blocker, PN-881, into Phase I studies.

Key Decisions for Investors

• Monitor the upcoming NDA filing for rusfertide and the subsequent opt-out decision with Takeda, as the potential ~$425 million payment and high-tier royalty stream represents a major non-dilutive funding and de-risking event.
• Track the commercial launch and clinical progress of icotrokinra by partner J&J, as its success in psoriasis and ongoing Phase III trials for other major indications could generate a substantial royalty stream, reinforcing the company's long-term financial stability.
• Consider the long-term optionality offered by the early-stage pipeline, particularly the oral obesity candidate PN-477, and anticipate initial clinical data readouts in 2026 which could serve as significant re-rating catalysts.
• Note the strategic shift to retain assets longer to clinical proof-of-concept before partnering, which suggests future collaborations may secure more favorable economics for Protagonist than the 2017 J&J deal.